Novartis's Zelnorm Enters Restricted Access Program

Law360, New York (July 27, 2007, 12:00 AM EDT) -- A few months after the U.S. Food and Drug Administration ordered it pulled from the market amid concerns about causing heart problems, Novartis AG's controversial drug Zelnorm will return under a restricted access program, announced the FDA and Novartis Friday.

The FDA has approved Zelnorm as a treatment investigational new drug. Women younger than 55 who suffer from either bowel syndrome with constipation or chronic idiopathic constipation for whom a doctor deems the drug medically necessary may consent to receive it, according to the FDA and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.